UCLA Awarded National Institute on Alcohol Abuse and Alcoholism Grant for Phase 2b Clinical Trial of MediciNova’s MN-166 (ibudilast) in Alcohol Use Disorder

UCLA Awarded National Institute on Alcohol Abuse and Alcoholism Grant for Phase 2b Clinical Trial of MediciNova’s MN-166 (ibudilast) in Alcohol Use Disorder

MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the National Institute on Alcohol Abuse and Alcoholism (NIAAA), which is part of...

Pin It on Pinterest